A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India

Sankhe, Ajay; Memane, Nanasaheb; Gawali, Vijaykumar; Memane, Sonal Nanasaheb; Ramakrishnan, Ganesh; Kundu, Tapanendu; Bagul, Mayur; Kumar, Ashotosh; Bansal, Vikram; Tiwari, Ravi

doi:10.1016/j.ctim.2022.102824

Cited by 10 publications

(14 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The detailed search result has been provided in Figure 1. After screening based on title/abstract, and full‐text, 13 studies with 991 patients were included (Abbaspour‐Aghdam et al, 2022; Ahmadi et al, 2021; Asadirad et al, 2022; Askari et al, 2022; Hartono Suryawati et al, 2022; Hellou et al, 2022; Khan et al, 2022; Majeed, Nagabhushanam, Shah, & Mundkur, 2021; Pawar et al, 2021; Sankhe et al, 2021; Sankhe et al, 2022; Tahmasebi et al, 2021; Valizadeh et al, 2020). The majority of the studies were conducted in Iran and India.…”

Section: Resultsmentioning

confidence: 99%

Curcumin for the treatment of COVID‐19 patients: A meta‐analysis of randomized controlled trials

Shafiee

Athar

Shahid

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

Curcumin is a low‐cost and easily accessible therapeutic option for COVID‐19 patients. We aimed to conduct a meta‐analysis to assess the effect of curcumin on clinical outcomes in COVID‐19 patients. Various databases, including PubMed, the Cochrane Library and Embase were searched from inception until October 2022 for randomized controlled trials (RCTs) evaluating curcumin use in COVID‐19 patients. Results from 13 RCTs were pooled using R software version 4.1.0. Curcumin reduced the risk of all‐cause mortality (RR 0.38; 95% CI: 0.20–0.72; moderate certainty of evidence), and patients with no recovery status (RR 0.54; 95% CI: 0.42–0.70; moderate certainty of evidence) but had no effect on the incidence of mechanical ventilation and hospitalization, and the rate of a positive viral PCR test. The results of subgroup analysis suggested a higher benefit with early administration of curcumin (within 5 days of onset of symptoms) and with the use of combination regimens. Curcumin is likely to be of benefit in mild‐to‐moderate COVID‐19 patients, but large‐scale RCTs are needed to confirm these findings. The limitations of our meta‐analysis include the small sample sizes of the included RCTs and the variable formulations of curcumin used across the studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Curcumin for the treatment of COVID‐19 patients: A meta‐analysis of randomized controlled trials

Shafiee

Athar

Shahid

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…Several studies investigated efficacy and safety of T&CM methods in the treatment of COVID 19 patients, including Chinese patent medicines Jing-Si Herbal Tea [ 48 ] and Lianhua Qingwen [ 49 ], flavonoids [ 50 ], and Ayurcov, a formulation made of ingredients mentioned in Ayurveda [ 51 ]. In addition, a retrospective study in Egypt included COVID 19 patients and their contacts who used TaibUVID nutritional supplement from prophetic medicine ( Nigella sativa , chamomile, and natural honey).…”

Section: Discussionmentioning

confidence: 99%

Use of traditional and complementary medicine for COVID 19 prophylaxis among healthcare professionals and students in Jordan: A cross-sectional study

Bulatova

Younes²,

Arabiyat³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Introduction There is inadequate evidence to recommend the use of any traditional and complementary medicine (T&CM) methods such as vitamin, mineral, herbal or other dietary supplements to prevent or treat COVID 19. Members of the medical team are particularly at risk of exposure to high viral load of coronavirus. They have also the best access to professional information regarding disease treatment and prophylaxis and disseminate such knowledge. The aim of the study was to assess the prevalence of use of T&CM for the prophylaxis of COVID 19 among the healthcare professionals and students in Jordan, along with the most common types and the factors associated with T&CM use. Methodology A cross-sectional study of T&CM use was conducted in Jordan using a snowball sampling method to distribute Google Forms and to enrol participants during coronavirus outbreak between June 10, 2021, and August 28, 2021. The study included healthcare professionals or students who consented to participate in the survey. The survey excluded those participants who had filled the questionnaire at least once or were pregnant/breast-feeding at the time of the study. The questionnaire consisted of 29 items, including screening, checkbox, dichotomous, matrix and open-ended questions. Results The response rate was 97.1%. Out of 560 study respondents, 359 (64.1%) reported using T&CM for COVID 19 prevention. Vitamins and nutrients were consumed by almost half (48.4%) of study participants, while nonpharmacological methods and herbal remedies were consumed by 35.2% and 25.2%, respectively. The most common source of information regarding T&CM use for COVID 19 prophylaxis included scientific publications (59.5%), followed by disease treatment guidelines (38.0%) and social media (32.3%). Adverse effects were reported by 8.5% and possible adverse effects were reported by another 8.5% of participants. The T&CM use was associated with working in contact with COVID 19 patients (OR: 1.625 (95% CI 1.047–2.523) (P = 0.03) and having a colleague as a source of information (OR: 1.720 (95% CI 1.026–2.883) (P = 0.04). Conclusions The prevalence of T&CM use for COVID 19 prevention among healthcare professionals and students in Jordan is high, with a significant proportion of participants reporting adverse effects. There is an urgent need for further research toward efficacy and safety of T&CM in COVID 19 prophylaxis as well as development of appropriate public health policy on this issue specific to each country.

show abstract

“…For example, an ayurvedic formulation containing C. longa , known as AyurCov, was found to relieve the symptoms associated with COVID-19 infections. Increased real-time reverse transcription polymerase chain reaction (rRT-PCR) cycle threshold (Ct) values and an improved functional status were also reported in patients consuming supplement . Valizadeh et al demonstrated that administration of 160 mg/day of nanocurcumin reduced mRNA and serum levels of IL-6 and IL-1β in 40 COVID-19 patients compared to placebo .…”

Section: Clinical Trials Of Turmeric and Curcuminmentioning

confidence: 99%

Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials

Kunnumakkara

Hegde

Dey

et al. 2023

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Turmeric (Curcuma longa) has been used for thousands of years for the prevention and treatment of various chronic diseases. Curcumin is just one of >200 ingredients in turmeric. Almost 7000 scientific papers on turmeric and almost 20,000 on curcumin have been published in PubMed. Scientific reports based on cell culture or animal studies are often not reproducible in humans. Therefore, human clinical trials are the best indicators for the prevention and treatment of a disease using a given agent/drug. Herein, we conducted an extensive literature survey on PubMed and Scopus following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The keywords "turmeric and clinical trials" and "curcumin and clinical trials" were considered for data mining. A total of 148 references were found to be relevant for the key term "turmeric and clinical trials", of which 70 were common in both PubMed and Scopus, 44 were unique to PubMed, and 34 were unique to Scopus. Similarly, for the search term "curcumin and clinical trials", 440 references were found to be relevant, of which 70 were unique to PubMed, 110 were unique to Scopus, and 260 were common to both databases. These studies show that the golden spice has enormous health and medicinal benefits for humans. This Review will extract and summarize the lessons learned about turmeric and curcumin in the prevention and treatment of chronic diseases based on clinical trials.

show abstract

A randomized, controlled, blinded, parallel group, clinical trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India

Cited by 10 publications

References 22 publications

Curcumin for the treatment of COVID‐19 patients: A meta‐analysis of randomized controlled trials

Curcumin for the treatment of COVID‐19 patients: A meta‐analysis of randomized controlled trials

Use of traditional and complementary medicine for COVID 19 prophylaxis among healthcare professionals and students in Jordan: A cross-sectional study

Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials

Contact Info

Product

Resources

About